The 30th JFCR-ISCC
New Antitumor Agents under Development in the US, Europe and Japan

2026 December 11 (Fri) 13:00 - 18:50
December 12 (Sat) 9:00 - 16:50

Yoshida Memorial Auditorium, JFCR
3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan

December 11 (Fri)

Session 1 13:00~ — Metabolic regulation to improve immune micro - environment

- **Ping-Chi Ho** *Ludwig Inst. for Cancer Research at UNIL, Switzerland*
  Can you remember, exhausted T cells?
- **Kenji Chamoto** *Kyoto University, Japan*
  Mitochondrial FAO prevents T cell exhaustion by reducing aldehyde
- **Shogo Kumagai** *Japanese Foundation for Cancer Research , Japan*
  Revealing the metabolic basis of cancer immunotherapy resistance

Meet-the-Expert Session 1
From Undruggable to Druggable

- **Charles G. Drake** *Johnson & Johnson Innovative Medicine*
  JNJ – 6143: A novel AR-targeted RIP-TAC for prostate cancer

Poster Flash Talks, Poster Viewing & Networking

December 12 (Sat)

Session 2 9:00~ — Revolution for pancreatic cancer therapy

- **Ida Aronchik** *Revolution Medicines, Inc.*
  Targeting oncogenic RAS with tri-complex inhibitors: Translational insights and strategies to overcome resistance
- **Adam Crystal** *Tango Therapeutics, Inc.*
  TBD
- **Atsushi Enomoto** *Nagoya University, Japan*
  Targeting cancer-associated fibroblast heterogeneity to enhance drug delivery

Meet-the-Expert Session 2

- **Ryan B. Corcoran** *Mass General Brigham Cancer Inst.*
  No longer undruggable: Advances in targeting RAS-driven cancers

Luncheon Seminar

- **Shunsuke Kitajima** *Japanese Foundation for Cancer Research , Japan*
  TBD

Session 3 13:20~ — Next-generation leadership session

- **Naofumi Uesaka** *Institute of Science Tokyo, Japan*
  Translating neural activity into oncogenic signaling in glioma
- **Israel Cañadas** *FOX Chase Cancer Ctr.*
  When tumors act like viruses: Exploiting viral mimicry for cancer therapy

Session 4 15:00~ — Other targets and drugs

- **Akiko Kimura** *Takeda Pharmaceutical Co., Ltd., Japan*
  Development of PD-1/IL-2α-bispecific fusion protein
- **Shinya Ishii** *Chugai Pharmaceutical Co., Ltd., Japan*
  Beyond binding: Expanding therapeutic possibilities through antibody engineering
- **Toshiyoshi Fujiwara** *Kagawa Rosai Hospital, Japan*
  Multidisciplinary oncolytic virotherapy for esophageal cancer patients unfit for standard treatments

Contact: Cancer Chemotherapy Center of JFCR
Mail: jfcr-iscc@ml.jfcr.or.jp

HP: https://iscc.umin.jp/

The 30th JFCR-ISCC is supported by following companies: MSD K.K., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., TOPPAN Holdings Inc., Taiho Pharmaceutical Co., Ltd.

Background Image was created by AI